Raphael Pharmaceutical INC

Raphael Pharmaceutical Inc. announced the voluntary resignations of its Chairman and CFO, along with the appointment of a new CFO.

Dr. Yehuda Eliya's term as a director of Raphael Pharmaceutical Inc. expired on December 31, 2025, with no reported disagreements.

Raphael Pharmaceutical Inc. announced a change to its Board of Directors with Dr. Igal Louria Hayon's resignation and Mr. Zvi Laufer Laor's appointment.

Raphael Pharmaceutical Inc. has completed development of its RaphaWell natural formula for rheumatoid arthritis support and is preparing for a U.S. launch following successful clinical trials.

Raphael Pharmaceuticals has expanded its board and appointed Ajay Kumar Dhadha as a new director and Chairman, replacing Shlomo Pilo.

Raphael Pharmaceuticals reports successful proof-of-concept study results for its cannabinoid-based formula in treating Rheumatoid Arthritis, showing significant improvements in patient health parameters.

Raphael Pharmaceutical Inc. reported a reduced net loss of $229,000 for Q1 2026, a 47% decrease from the prior year, driven by lower R&D and G&A expenses, though the company continues to face going concern uncertainties.

Raphael Pharmaceutical Inc. reports significant liquidity challenges and a going concern warning despite positive clinical study results and a new product launch.

Raphael Pharmaceutical Inc. reported continued net losses and a going concern warning, despite launching its RaphaWell formula for rheumatoid arthritis support as a dietary supplement.

Raphael Pharmaceutical Inc.'s Q1 2025 results show a decrease in research and development expenses offset by an increase in general and administrative costs, with the company continuing to focus on cannabinoid-based drug development.

Raphael Pharmaceutical Inc. reported a decrease in operating loss for the third quarter of 2024, driven by reduced research and development expenses, as the company continues its clinical development programs.

Raphael Pharmaceutical Inc. reported a net loss of $798,000 for the six months ended June 30, 2024, as the company continues to invest in research and development.

Raphael Pharmaceutical Inc. reports a successful RA product launch and provisional patent filing, but faces significant operating losses and going concern doubts.

Raphael Pharmaceuticals Inc. reports its annual results on Form 10-K, highlighting continued operating losses and the necessity for substantial additional funding to advance its pharmaceutical drug product candidates.

Raphael Pharmaceutical Inc. extends a board member's appointment and provides an update on its pre-clinical development of cannabinoid-based therapies for rheumatoid arthritis and COVID-19 related inflammation in its annual report.

Raphael Pharmaceutical Inc. Chief Technology Officer, Hayon Igal Louria, exercised warrants to acquire 350,000 shares of common stock.

Director Yehuda Eliya reports the expiration of 202,000 warrants and receipt of 200,000 new warrants in Raphael Pharmaceuticals.

Raphael Pharmaceuticals CEO Shlomo Pilo reports acquiring 200,000 shares of common stock and warrants to purchase 100,000 shares at $0.50 per share and warrant.

Director Ajay Kumar Dhadha receives 350,000 shares of common stock and warrants for 250,000 shares as compensation for his service as a director and chairman of Raphael Pharmaceuticals.

Director Eliya Yehuda reports acquiring 150,000 shares of Raphael Pharmaceutical Inc. common stock at $0.40 per share and disposing of 352,000 shares.

Igal Louria Hayon, Chief Technology Officer of Raphael Pharmaceutical Inc., exercised warrants to purchase 999,000 shares of common stock at $0.01 per share on August 29, 2023.

Raphael Pharmaceutical Inc. has amended its Articles of Incorporation to increase the authorized shares of common stock from 21,020,560 to 50,000,000, approved by a majority of stockholders via written consent.

Raphael Pharmaceutical is registering for the resale of up to 5,787,027 shares of its common stock by selling security holders.